Current status and progress of pancreatic cancer in China

World Journal of Gastroenterology

Volumn 21, Issue 26, 2015, Pages 7988-8003

  Lin, Quan Jun ^a   Yang, Feng ^a   Jin, Chen ^a   Fu, De Liang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Diagnosis; Incidence; Pancreatic cancer; Treatment

Indexed keywords

CARBOHYDRATE ANTIGEN; CURCUMIN; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; AWARENESS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHINA; CHINESE; CHINESE MEDICINE; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DEVELOPED COUNTRY; DIABETES MELLITUS; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; GENETIC RISK; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; REVIEW; TOBACCO USE; ASIAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; ETHNOLOGY; INCIDENCE; LIFESTYLE; MORTALITY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE; RISK FACTOR; SOCIOECONOMICS; TIME FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COMORBIDITY; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; LIFE STYLE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84936990220     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i26.7988     Document Type: Review

References (112)

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039-1049 [PMID: 25207767 DOI: 10.1056/NEJMra1404198]
2. Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 2007; 16: 546-552 [PMID: 17372250 DOI: 10.1158/1055-9965. EPI-06-0893]
3. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 2010; 39: 458-462 [PMID: 19924019 DOI: 10.1097/MPA.0b013e3181bd6489]
4. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 2015; 385: 1206-1218 [PMID: 25479696 DOI: 10.1016/S0140-6736(14)61396-9]
5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available from: URL: http://globocan. iarc.fr, accessed on 18/1/2015
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]
7. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014; 2: 61 [PMID: 25333036 DOI: 10.3978/j.issn.2305-5839.201 4.04.05]
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073]
9. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 2013; 25: 10-21 [PMID: 23372337 DOI: 10.3978/j.issn.1000-9604.2012.12.04]
10. He J, Chen WQ. Chinese Cancer Registry Annual Report 2012. Beijing: Press of Military Medical Sciences, 2012: 68-71
11. Chen WQ, Liang D, Zhang SW, Zheng RS, He YT. Pancreatic cancer incidence and mortality patterns in china, 2009. Asian Pac J Cancer Prev 2013; 14: 7321-7324 [PMID: 24460295 DOI: 10.7314/APJCP.2013.14.12.7321]
12. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench 2015; 8: 19-27 [PMID: 25584172]
13. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007; 14: 1320-1326 [PMID: 17225980 DOI: 10.1245/s10434-006-9249-8]
14. Watts J. China's environmental health challenges. Lancet 2008; 372: 1451-1452 [PMID: 18975391]
15. Kan H. Environment and health in china: challenges and opportunities. Environ Health Perspect 2009; 117: A530-A531 [PMID: 20049177 DOI: 10.1289/ehp.0901615]
16. Jemal A, Simard EP, Xu J, Ma J, Anderson RN. Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007. Cancer Causes Control 2013; 24: 559-565 [PMID: 22729932 DOI: 10.1007/s10552-012-9993-y]
17. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413 [PMID: 19561064 DOI: 10.1093/aje/kwp134]
18. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
19. Wang Y, Duan H, Yang X, Guo J. Cigarette smoking and the risk of pancreatic cancer: a case-control study. Med Oncol 2014; 31: 184 [PMID: 25159284 DOI: 10.1007/s12032-014-0184-4]
20. Yin M, Ma C, Liu S, Qian P, Zhang M, Chen W, Zheng R, Zhang S, Sun X. Cigarette Smoking and The Risk of Pancreatic Cancer: A Case-control Study. Zhongguo Zhongliu 2014; 3: 200-204
21. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, Michaud DS, Severinsen MT, Overvad K, Olsen A, Tjønneland A, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Rohrmann S, Boeing H, Nöthlings U, Trichopoulou A, Moutsiou E, Dilis V, Palli D, Krogh V, Panico S, Tumino R, Vineis P, van Gils CH, Peeters PH, Lund E, Gram IT, Rodríguez L, Agudo A, Larrañaga N, Sánchez MJ, Navarro C, Barricarte A, Manjer J, Lindkvist B, Sund M, Ye W, Bingham S, Khaw KT, Roddam A, Key T, Boffetta P, Duell EJ, Jenab M, Gallo V, Riboli E. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 126: 2394-2403 [PMID: 19790196 DOI: 10.1002/ijc.24907]
22. Chuang SC, Gallo V, Michaud D, Overvad K, Tjønneland A, Clavel-Chapelon F, Romieu I, Straif K, Palli D, Pala V, Tumino R, Sacerdote C, Panico S, Peeters PH, Lund E, Gram IT, Manjer J, Borgquist S, Riboli E, Vineis P. Exposure to environmental tobacco smoke in childhood and incidence of cancer in adulthood in never smokers in the European Prospective Investigation into Cancer and Nutrition. Cancer Causes Control 2011; 22: 487-494 [PMID: 21279734 DOI: 10.1007/s10552-010-9723-2]
23. Wörmann SM, Algül H. Risk factors and therapeutic targets in pancreatic cancer. Front Oncol 2013; 3: 282 [PMID: 24303367 DOI: 10.3389/fonc.2013.00282]
24. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301: 2553-2562 [PMID: 19549972 DOI: 10.1001/jama.2009.886]
25. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007; 120: 1993-1998 [PMID: 17266034 DOI: 10.1002/ijc.22535]
26. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 2012; 51: 53-63 [PMID: 22162231 DOI: 10.1002/mc.20778]
27. Larsson SC, Håkansson N, Giovannucci E, Wolk A. Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst 2006; 98: 407-413 [PMID: 16537833 DOI: 10.1093/jnci/djj094]
28. Jansen RJ, Robinson DP, Stolzenberg-Solomon RZ, Bamlet WR, de Andrade M, Oberg AL, Rabe KG, Anderson KE, Olson JE, Sinha R, Petersen GM. Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer. J Gastrointest Cancer 2013; 44: 152-161 [PMID: 23620017 DOI: 10.1007/s12029-012-9441-y]
29. Liu SZ, Chen WQ, Wang N, Yin MM, Sun XB, He YT. Dietary factors and risk of pancreatic cancer: a multi-centre case-control study in China. Asian Pac J Cancer Prev 2014; 15: 7947-7950 [PMID: 25292092 DOI: 10.7314/APJCP.2014.15.18.7947]
30. Wang J, Zhang W, Sun L, Yu H, Ni QX, Risch HA, Gao YT. Dietary energy density is positively associated with risk of pancreatic cancer in urban Shanghai Chinese. J Nutr 2013; 143: 1626-1629 [PMID: 23902959 DOI: 10.3945/jn.113.178129]
31. Soliman PT, Cui X, Zhang Q, Hankinson SE, Lu KH. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol 2011; 204: 167.e1-167. e5 [PMID: 21047616 DOI: 10.1016/j.ajog.2010.08.045]
32. Zhang J, Dhakal IB, Gross MD, Lang NP, Kadlubar FF, Harnack LJ, Anderson KE. Physical activity, diet, and pancreatic cancer: a population-based, case-control study in Minnesota. Nutr Cancer 2009; 61: 457-465 [PMID: 19838917 DOI: 10.1080/01635580902 718941]
33. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101 [PMID: 18061176 DOI: 10.1053/j.gastro.2007.10.040]
34. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profle of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987 [PMID: 18395079 DOI: 10.1053/j.gastro.2008.01.039]
35. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605-1609 [PMID: 7745774 DOI: 10.1001/jama.1995.03520440059037]
36. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083 [PMID: 15886696 DOI: 10.1038/sj.bjc.6602619]
37. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-1937 [PMID: 21458985 DOI: 10.1016/j.ejca.2011.03.003]
38. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88-95 [PMID: 19111249 DOI: 10.1016/S1470-2045(08)70337-1]
39. Zhang PH, Chen ZW, Lv D, Xu YY, Gu WL, Zhang XH, Le YL, Zhu HH, Zhu YM. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health 2012; 12: 567 [PMID: 22839452 DOI: 10.1186/147 1-2458-12-567]
40. Kuang TT, Jin da Y, Wang DS, Xu XF, Ni XL, Wu WC, Lou WH. Clinical epidemiological analysis of the relationship between pancreatic cancer and diabetes mellitus: data from a single institution in China. J Dig Dis 2009; 10: 26-29 [PMID: 19236544 DOI: 10.1111/j.1751-2980.2008.00359.x]
41. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009; 133: 365-374 [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365]
42. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol 2014; 12: 715-727; quiz e41-3 [PMID: 23891921 DOI: 10.1016/j.cgh.2013.06.031]
43. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 2012; 9: 445-453 [PMID: 22664588 DOI: 10.1038/nrgastro.2012.111]
44. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358 [PMID: 20510834 DOI: 10.1016/j.bpg.2010.02.007]
45. Lin G, Zeng Z, Wang X, Wu Z, Wang J, Wang C, Sun Q, Chen Y, Quan H. Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Cancer Causes Control 2012; 23: 59-67 [PMID: 22008981 DOI: 10.1007/s10552-011-9856-y]
46. Gong Y, Zhou Q, Zhou Y, Lin Q, Zeng B, Chen R, Li Z. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. Cancer Causes Control 2012; 23: 1279-1288 [PMID: 22674223 DOI: 10.1007/s10552-012-0005-z]
47. Han-You X. Chronic infection and other risk factors of cancer in China and other countries. Ann Oncol 2013; 24: 267 [PMID: 23251013 DOI: 10.1093/annonc/mds598]
48. Matthaei H, Schulick RD, Hruban RH, Maitra A. Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 141-150 [PMID: 21383670 DOI: 10.1038/nrgastro.2011.2]
49. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014; 15: 489-538 [PMID: 24731404 DOI: 10.1016/S1470-2045(14)70029-4]
50. Ancona C, Badaloni C, Mataloni F, Bolignano A, Bucci S, Cesaroni G, Sozzi R, Davoli M, Forastiere F. Mortality and morbidity in a population exposed to multiple sources of air pollution: A retrospective cohort study using air dispersion models. Environ Res 2015; 137: 467-474 [PMID: 25701728 DOI: 10.1016/j.envres.2014.10.036]
51. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffn CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113 [PMID: 20981101 DOI: 10.1038/nature09460]
52. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117 [PMID: 20981102 DOI: 10.1038/nature09515]
53. Chu D, Kohlmann W, Adler DG. Identifcation and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 2010; 11: 203-212 [PMID: 20442513]
54. Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004; 28: 235-240 [PMID: 15084963]
55. Ariyama J, Suyama M, Ogawa K, Ikari T. [Screening of pancreatic neoplasms and the diagnostic rate of small pancreatic neoplasms]. Nihon Rinsho 1986; 44: 1729-1734 [PMID: 3537369]
56. Zhao YP. Pay attention to early diagnosis: the key to overcome pancreatic cancer. Zhonghua Wai Ke Zazhi 2001; 39: 261-262
57. Ni QX, Yang F. Regulate diagnosis and treatment, increase the long-term survival rate of pancreatic cancer. Zhongguo Puwai Jizhu Yu Linchuang Zazhi 2006; 13: 493-495
58. Stoita A, Penman ID, Williams DB. Review of screening for pancreatic cancer in high risk individuals. World J Gastroenterol 2011; 17: 2365-2371 [PMID: 21633635 DOI: 10.3748/wjg.v17. i19.2365]
59. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol 2014; 20: 7864-7877 [PMID: 24976723 DOI: 10.3748/wjg.v20.i24.7864]
60. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013; 257: 17-26 [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb]
61. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
62. Hanada K, Okazaki A, Hirano N, Izumi Y, Teraoka Y, Ikemoto J, Kanemitsu K, Hino F, Fukuda T, Yonehara S. Diagnostic strategies for early pancreatic cancer. J Gastroenterol 2015; 50: 147-154 [PMID: 25501287 DOI: 10.1007/s00535-014-1026-z]
63. Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, Wu C, Ni QX, Li M, Yu X. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 2014; 346: 273-277 [PMID: 24462819 DOI: 10.1016/j.canlet.2014.01.004]
64. Topazian M, Enders F, Kimmey M, Brand R, Chak A, Clain J, Cunningham J, Eloubeidi M, Gerdes H, Gress F, Jagannath S, Kantsevoy S, LeBlanc JK, Levy M, Lightdale C, Romagnuolo J, Saltzman JR, Savides T, Wiersema M, Woodward T, Petersen G, Canto M. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007; 66: 62-67 [PMID: 17382940 DOI: 10.1016/j.gie.2006.09.018]
65. Zhao YP. The present situation and the future of diagnosis and treatment of pancreatic cancer. Zhonghua Waike Zazhi 2014; 52: 641-643
66. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 2012; 6: 597-612 [PMID: 23075238 DOI: 10.2217/bmm.12.69]
67. Chen Y, Hao J, Ma W, Tang Y, Gao C, Hao X. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. J Gastrointest Surg 2011; 15: 1026-1034 [PMID: 21484493 DOI: 10.1007/s11605-011-1493-y]
68. Zhang QH, Ni QX. [Clinical analysis of 2340 cases of pancreatic cancer]. Zhonghua Yi Xue Zazhi 2004; 84: 214-218 [PMID: 15059537]
69. Luo J, Xiao L, Wu C, Zheng Y, Zhao N. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004-2009. PLoS One 2013; 8: e76052 [PMID: 24130758 DOI: 10.1371/journal.pone.0076052]
70. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 2015; Epub ahead of print [PMID: 25636698 DOI: 10.1136/gutjnl-2014-308653]
71. Bassi C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P. Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 2001; 18: 453-457; discussion 458 [PMID: 11799295]
72. Clarke CN, Sussman JJ, Abbott DE, Ahmad SA. Factors affecting readmission after pancreaticoduodenectomy. Adv Surg 2013; 47: 99-110 [PMID: 24298846]
73. Lee GC, Fong ZV, Ferrone CR, Thayer SP, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. High performing whipple patients: factors associated with short length of stay after open pancreati-coduodenectomy. J Gastrointest Surg 2014; 18: 1760-1769 [PMID: 25091843 DOI: 10.1007/s11605-014-2604-3]
74. Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB. Comprehensive preoperative assessment of pancreatic adenocar-cinoma with 64-section volumetric CT. Radiographics 2007; 27: 1653-1666 [PMID: 18025509 DOI: 10.1148/rg.276075034]
75. Yang F, Jin C, Fu D. Celiac axis compression syndrome and pancreatic head cancer. Pancreatology 2014; 14: 310-311 [PMID: 25207337]
76. Gusmini S, Nicoletti R, Martinenghi C, Del Maschio A. Vascular involvement in periampullary tumors: MDCT, EUS, and CDU. Abdom Imaging 2009; 34: 514-522 [PMID: 18587612 DOI: 10.1007/s00261-008-9439-x]
77. Sandrasegaran K, Lin C, Akisik FM, Tann M. State-of-the-art pancreatic MRI. AJR Am J Roentgenol 2010; 195: 42-53 [PMID: 20566796 DOI: 10.2214/AJR.10.4421]
78. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol 2012; 199: 952-967 [PMID: 23096166 DOI: 10.2214/AJR.11.8182]
79. Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 2014; 20: 15580-15589 [PMID: 25400441 DOI: 10.3748/wjg.v20.i42.15580]
80. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-332 [PMID: 15044750 DOI: 10.1148/radiol.2312021185]
81. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238: 405-422 [PMID: 16436809 DOI: 10.1148/radiol.2382041977]
82. Ngamruengphong S, Swanson KM, Shah ND, Wallace MB. Preoperative endoscopic ultrasound-guided fne needle aspiration does not impair survival of patients with resected pancreatic cancer. Gut 2015; 64: 1105-1110 [PMID: 25575893 DOI: 10.1136/gutjnl-2014-307475]
83. Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007; 94: 265-273 [PMID: 17318801]
84. Yan JF, Xu XW, Jin WW, Huang CJ, Chen K, Zhang RC, Harsha A, Mou YP. Laparoscopic spleen-preserving distal pancreatectomy for pancreatic neoplasms: a retrospective study. World J Gastroenterol 2014; 20: 13966-13972 [PMID: 25320534 DOI: 10.3748/wjg.v20. i38.13966]
85. Zhan Q, Deng XX, Han B, Liu Q, Shen BY, Peng CH, Li HW. Robotic-assisted pancreatic resection: a report of 47 cases. Int J Med Robot 2013; 9: 44-51 [PMID: 23225335 DOI: 10.1002/rcs.1475]
86. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012; 255: 1048-1059 [PMID: 22511003 DOI: 10.1097/SLA.0b013e318251ee09]
87. Daouadi M, Zureikat AH, Zenati MS, Choudry H, Tsung A, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ. Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg 2013; 257: 128-132 [PMID: 22868357 DOI: 10.1097/SLA.0b013e31825fff08]
88. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, Kendrick ML. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014; 260: 633-638; discussion 638-640 [PMID: 25203880 DOI: 10.1097/SLA.0000000000000937]
89. Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J, Yang F, Ni QX. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl) 2009; 122: 284-290 [PMID: 19236805]
90. Yang F, Di Y, Li J, Wang X Y, Yao L, Hao SJ, Jiang YJ, Jin C, Fu DL. Accuracy of routine multidetector computed tomography to identify arterial variants in patients scheduled for pancreati-coduodenectomy. World J Gastroenterol 2015; 21: 969-976 [PMID: 25624732 DOI: 10.3748/wjg.v21.i3.969]
91. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
92. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]
93. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-1648 [PMID: 23547081 DOI: 10.1200/JCO.2012.43.3680]
94. Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2013; 71: 1065-1072 [PMID: 23483298 DOI: 10.1007/s00280-013-2102-4]
95. Ge F, Xu N, Bai Y, Ba Y, Zhang Y, Li F, Xu H, Jia R, Wang Y, Lin L, Xu J. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 2014; 19: 1133-1134 [PMID: 25273077 DOI: 10.1634/theoncologist.2014-0223]
96. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677]
97. Guo XZ, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol 2013; 5: 20-28 [PMID: 23556053 DOI: 10.4251/wjgo.v5.i2.20]
98. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237 [PMID: 19307500 DOI: 10.1200/JCO.2008.20.0238]
99. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622 [PMID: 20606091 DOI: 10.1200/JCO.2010.28.1386]
100. Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 2014; 120: 1171-1177 [PMID: 24390779 DOI: 10.1002/cncr.28543]
101. Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radio-chemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol 2013; 19: 7461-7471 [PMID: 24259979 DOI: 10.3748/wjg.v19.i42.7461]
102. Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. World J Gastroenterol 2014; 20: 13987-13992 [PMID: 25320537 DOI: 10.3748/wjg.v20.i38.13987]
103. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol 2014; 15: e279-e289 [PMID: 24872111 DOI: 10.1016/S1470-2045(13)70567-9]
104. McQuade JL, Meng Z, Chen Z, Wei Q, Zhang Y, Bei W, Palmer JL, Cohen L. Utilization of and Attitudes towards Traditional Chinese Medicine Therapies in a Chinese Cancer Hospital: A Survey of Patients and Physicians. Evid Based Complement Alternat Med 2012; 2012: 504507 [PMID: 23093982 DOI: 10.1155/2012/504507]
105. Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer 2012; 107: 411-416 [PMID: 22782343 DOI: 10.1038/bjc.2012.283]
106. Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med 2013; 19: 20-22 [PMID: 23594449]
107. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499 [PMID: 18628464]
108. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-164 [PMID: 20859741 DOI: 10.1007/s00280-010-1470-2]
109. Yang F, Jin C, Subedi S, Lee CL, Wang Q, Jiang Y, Li J, Di Y, Fu D. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev 2012; 38: 566-579 [PMID: 22655679 DOI: 10.1016/j.ctrv.2012.02.003]
110. Yang F, Jin C, Jiang Y, Li J, Di Y, Ni Q, Fu D. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011; 37: 633-642 [PMID: 21330062 DOI: 10.1016/j.ctrv.2011.01.006]
111. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010; 16: 5028-5037 [PMID: 20876795 DOI: 10.1158/1078-0432.CCR-09-3209]
112. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin 2013; 63: 318-348 [PMID: 23856911 DOI: 10.3322/caac.21190]